Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct;52(Pt 2):178-188.
doi: 10.1016/j.semcancer.2017.11.003. Epub 2017 Nov 6.

Breast cancer genomics and immuno-oncological markers to guide immune therapies

D Hammerl  1 , M Smid  1 , A M Timmermans  1 , S Sleijfer  1 , J W M Martens  1 , R Debets  2
Affiliations
Free article
Review

Breast cancer genomics and immuno-oncological markers to guide immune therapies

D Hammerl et al. Semin Cancer Biol. 2018 Oct.
Free article

Abstract

There is an increasing awareness of the importance of tumor - immune cell interactions to the evolution and therapy responses of breast cancer (BC). Not surprisingly, numerous studies are currently assessing the clinical value of immune modulation for BC patients. However, till now durable clinical responses are only rarely observed. It is important to realize that BC is a heterogeneous disease comprising several histological and molecular subtypes, which cannot be expected to be equally immunogenic and therefore not equally sensitive to single immune therapies. Here we review the characteristics of infiltrating leukocytes in healthy and malignant breast tissue, the prognostic and predictive values of immune cell subsets across different BC subtypes and the various existing immune evasive mechanisms. Furthermore, we describe the presence of certain groups of antigens as putative targets for treatment, evaluate the outcomes of current clinical immunotherapy trials, and finally, we propose a strategy to better implement immuno-oncological markers to guide future immune therapies in BC.

Keywords: Antigens; Breast cancer; Immune evasive mechanisms; Immune-oncological markers; Immunotherapy; TILs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Substances